Dies ist eine Übersichtsseite mit Metadaten zu dieser wissenschaftlichen Arbeit. Der vollständige Artikel ist beim Verlag verfügbar.
Amiodarone or an Implantable Cardioverter–Defibrillator for Congestive Heart Failure
6.486
Zitationen
17
Autoren
2005
Jahr
Abstract
In patients with NYHA class II or III CHF and LVEF of 35 percent or less, amiodarone has no favorable effect on survival, whereas single-lead, shock-only ICD therapy reduces overall mortality by 23 percent.
Ähnliche Arbeiten
Corrigendum to: 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC.
2021 · 19.535 Zit.
2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
2021 · 12.105 Zit.
2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
2016 · 11.366 Zit.
ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC
2012 · 6.890 Zit.
Prophylactic Implantation of a Defibrillator in Patients with Myocardial Infarction and Reduced Ejection Fraction
2002 · 6.828 Zit.